Key facts
- This page summarizes John Oyler's Form 4 filing for BeOne Medicines Ltd. (ONC).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jun 2026, 17:15.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Sale
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
Footnote F2
These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
Footnote F3
These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
Footnote F4
These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
Footnote F5
These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
Footnote F6
Each American Depositary Share represents 13 Ordinary Shares.
Footnote F7
The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon change of control or certain termination events.
Footnote F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.655 to $273.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Footnote F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.74 to $274.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Footnote F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.93 to $275.21, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.